文献速递细胞病理与分子病理

从涂片到测序:甲状腺细胞学涂片用于ThyroSeq分子分析及61个检测结节的临床病理洞察

From Smear to Sequence: Using Thyroid Cytology Smear Slides for ThyroSeq Molecular Analysis and Clinicopathologic Insights From 61 Tested Nodules.
PubMed 文献 · Arch Pathol Lab Med · 2025-10-06

本研究开发软件解析非结构化ThyroSeq报告以提取可操作数据,并数字化涂片以替代标本记录,对59例病例的61份甲状腺细针穿刺标本进行ThyroSeq检测。所有61份标本DNA分析均合格,仅1份RNA分析不合格;8例中涂片是唯一可行样本,21份(34.4%)ThyroSeq阳性,最常见为基因突变(13份阳性标本中检出16个突变)。

要点

  • 甲状腺细胞学涂片可用于ThyroSeq分子检测,尤其当常规样本类型不可用时。
  • 61份涂片标本DNA分析全部合格,RNA分析仅1份不合格。
  • 34.4%的标本ThyroSeq阳性,基因突变最常见。

核心结论

  • 甲状腺细胞学涂片可扩展用于分子分析,尤其在常规样本类型不可用时,高合格率和分子改变成功检出减少重复操作并简化诊疗。

研究设计与样本

  • 开发软件解析非结构化ThyroSeq报告以提取可操作数据,数字化涂片创建替代标本记录,并记录队列中病例的临床、分子和病理发现。
  • 共提交59例病例的61份甲状腺细针穿刺标本进行ThyroSeq检测。

主要发现

  • 所有61份标本DNA分析均合格,仅1份RNA分析不合格。
  • 8例中涂片是分子检测的唯一可行样本。
  • 21份标本(34.4%)ThyroSeq结果阳性。
  • 基因突变最常见,13份阳性标本中检出16个突变;还识别了拷贝数改变、基因表达改变和基因融合。

关键数值与推荐

  • 61份标本中21份(34.4%)ThyroSeq阳性。
  • 13份阳性标本中检出16个基因突变。

临床怎么用

  • 当常规检测介质不可用时,可使用甲状腺细胞学涂片进行ThyroSeq分子分析。
  • 临床与细胞学团队间有效沟通对管理额外工作量至关重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT.—: In the absence of conventional testing media, thyroid cytology smear slides may be used for molecular analysis of nodules with indeterminate cytology results. OBJECTIVE.—: To present solutions for overcoming challenges of ThyroSeq testing using smear slides and report findings from tested nodules. DESIGN.—: We developed software to parse unstructured ThyroSeq reports for actionable data extraction. To ensure compliance with sample retention requirements, substitute specimen records were created by digitizing smear slides before they were exhausted for molecular analysis. We streamlined the test send-out process and recorded the clinical, molecular, and pathologic findings of the cases in our cohort. RESULTS.—: We submitted 61 thyroid fine-needle aspiration specimens from 59 cases for ThyroSeq testing. All 61 specimens were adequate for DNA analysis, and only 1 was insufficient for RNA analysis. In 8 cases, the smear slide was the only viable sample for molecular testing. A total of 21 specimens (34.4%) had a positive ThyroSeq result. Gene mutations were the most common findings, with 16 mutations detected in 13 "positive" specimens. Additionally, copy number alterations, gene expression alterations, and gene fusions were identified. CONCLUSIONS.—: This study presents our approach to extending the utility of thyroid cytology smear slides by enabling molecular analysis, particularly when routine sample types are unavailable. High adequacy rates and successful detection of molecular alterations highlight the potential of smear slides in molecular testing, reducing the need for repeated procedures and streamlining care. Effective communication between clinical and cytology teams remains essential to manage the additional workload.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Trabzonlu L, Elliott C, Fisch AS, et al. From Smear to Sequence: Using Thyroid Cytology Smear Slides for ThyroSeq Molecular Analysis and Clinicopathologic Insights From 61 Tested Nodules. Arch Pathol Lab Med. 2025. PMID: 41051104. doi:10.5858/arpa.2025-0115-OA

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。